ACM
SCLN

Ativo Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Ativo Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-123,428
Closed -$1.21M – 246
2017
Q1 		$1.21M Hold
123,428
– – 0.3% 124
2016
Q4 		$1.33M Buy
123,428
+5,200
+4% +$52K 0.31% 105
2016
Q3 		$1.21M Buy
118,228
+20,222
+21% +$220K 0.28% 113
2016
Q2 		$1.28M Buy
98,006
+27,768
+40% +$364K 0.31% 100
2016
Q1 		$773K Sell
70,238
-4,800
-6% -$42.7K 0.21% 92
2015
Q4 		$690K Buy
75,038
+700
+0.9% +$5.86K 0.17% 101
2015
Q3 		$592K Buy
74,338
+2
+0% +$17 0.16% 126
2015
Q2 		$657K Buy
74,336
+2,773
+4% +$25.3K 0.23% 82
2015
Q1 		$634K Sell
71,563
-6
-0% -$48 0.25% 86
2014
Q4 		$627K Hold
71,569
– – 0.26% 89
2014
Q3 		$493K Buy
+71,569
New +$429K 0.19% 97
2013
Q3 		– Sell
-74,545
Closed -$370K – 207
2013
Q2 		$370K Buy
+74,545
New +$355K 0.19% 114

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ativo Capital Management's SCLN Position: Q2 2017 in Review

Ativo Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2017, closing a stake of 123,428 shares — an estimated $1.21M sold.

Ativo Capital Management first reported a position in SCLN in Q2 2013 and held it in 12 quarters. The position peaked at $1.33M in Q4 2016. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.

  • Ativo Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Ativo Capital Management sold 123,428 Sciclone Pharmaceuticals Inc shares in Q2 2017, an estimated $1.21M.
  • Ativo Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
  • Ativo Capital Management's Sciclone Pharmaceuticals Inc position peaked at $1.33M in Q4 2016.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2017.

Based on Ativo Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.